Want to see GDTC full AI Analyst Report?
CytoMed Therapeutics Limited (GDTC) Income Statement
CytoMed Therapeutics Limited Income Statement
Last quarter (Q2 2026), CytoMed Therapeutics Limited's total revenue was $157.29K, an increase of 0.90% from the same quarter last year. In Q2, CytoMed Therapeutics Limited's net income was $-1.77M. See CytoMed Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 324.39K | $ 69.50K | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 256.39K | $ 52.38K | $ -4.36M | $ 0.00 | $ 110.29K | |
| $ 5.05M | $ 3.65M | $ 0.00 | $ 2.34M | $ 1.27M | |
| Depreciation and Amortization | $ 401.58K | $ 335.36K | $ 381.15K | $ 392.87K | $ 329.88K |
| $ -3.57M | $ -2.17M | $ -3.70M | $ -2.61M | $ -1.56M | |
| $ -4.79M | $ -3.60M | $ -4.36M | $ -2.34M | $ -1.16M | |
| $ 792.74K | $ 1.08M | $ 228.51K | $ -789.97K | $ -900.44K | |
| $ -4.00M | $ -2.52M | $ -4.13M | $ -3.13M | $ -2.06M | |
| $ -3.98M | $ -2.52M | $ -4.13M | $ -3.13M | $ -2.07M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.34 | $ -0.22 | $ -0.39 | $ -0.40 | $ -0.30 |
| Diluted EPS | $ -0.34 | $ -0.22 | $ -0.39 | $ -0.40 | $ -0.30 |
| Weighted Average Shares Outstanding | 11.65M | 11.54M | 10.63M | 7.92M | 6.93M |
| Weighted Average Shares Outstanding (Diluted) | 11.65M | 11.54M | 10.63M | 7.92M | 6.93M |
Currency in SGD
